Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

[1]  Drew M Pardoll,et al.  Cancer immunotherapy comes of age. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  B. Levine,et al.  The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells , 2011, Science Translational Medicine.

[3]  W. Zou,et al.  Dual biological effects of the cytokines interleukin-10 and interferon-γ , 2011, Cancer Immunology, Immunotherapy.

[4]  G. Freeman,et al.  The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo , 2011, The Journal of Immunology.

[5]  D. Munn,et al.  Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. , 2011, Blood.

[6]  T. Okazaki,et al.  PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice , 2011, The Journal of experimental medicine.

[7]  G. Freeman,et al.  Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques. , 2010, The Journal of clinical investigation.

[8]  M. Caligiuri,et al.  The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. , 2010, Blood.

[9]  S. Anand,et al.  B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. , 2010, Blood.

[10]  J. Taube,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Lloyd J. Old,et al.  Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer , 2010, Proceedings of the National Academy of Sciences.

[12]  Loise M. Francisco,et al.  PD-L1 regulates the development, maintenance, and function of induced regulatory T cells , 2009, The Journal of experimental medicine.

[13]  W. Isaacs,et al.  Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+ , 2009, The Prostate.

[14]  S. Rosenberg,et al.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. , 2009, Blood.

[15]  S. Quezada,et al.  Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies , 2009, The Journal of experimental medicine.

[16]  J. Kirkwood,et al.  PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients1 , 2009, The Journal of Immunology.

[17]  T. Nomura,et al.  CTLA-4 Control over Foxp3+ Regulatory T Cell Function , 2008, Science.

[18]  Lieping Chen,et al.  Inhibitory B7-family molecules in the tumour microenvironment , 2008, Nature Reviews Immunology.

[19]  R. Berger,et al.  Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies , 2008, Clinical Cancer Research.

[20]  G. Zhu,et al.  B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. , 2008, Blood.

[21]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[22]  G. Freeman,et al.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.

[23]  T. Okazaki,et al.  PD-1 and PD-1 ligands: from discovery to clinical application. , 2007, International immunology.

[24]  R. Ahmed,et al.  Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.

[25]  Jeung-Hoon Lee,et al.  IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells. , 2005, Journal of dermatological science.

[26]  Lieping Chen,et al.  Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells. , 2005, American journal of respiratory cell and molecular biology.

[27]  T. Okazaki,et al.  Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Lieping Chen,et al.  In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses , 2005, The Journal of experimental medicine.

[29]  Tasuku Honjo,et al.  PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells , 2004, Cancer Research.

[30]  Yoshimasa Tanaka,et al.  Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice , 2003, Nature Medicine.

[31]  L. Staudt,et al.  Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma , 2003, The Journal of experimental medicine.

[32]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[34]  D. Pardoll,et al.  B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells , 2001, The Journal of experimental medicine.

[35]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[36]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[37]  G. Zhu,et al.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.

[38]  T. Honjo,et al.  Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. , 1999, Immunity.

[39]  T. Honjo,et al.  Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. , 1992, The EMBO journal.

[40]  P. Linsley,et al.  T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Antonio Polley,et al.  Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection , 2009, Nature Immunology.

[42]  G. Freeman,et al.  The B7 family revisited. , 2005, Annual review of immunology.